PSMA-Targeted [In-111]-Labeled Trillium Compound

N/A

Report date: 2025/11/21 17:16:38

NME

Base Information

Drug NamePSMA-Targeted [In-111]-Labeled Trillium Compound

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Indium > 111In +[4]

Mechanisms of ActionPositron-emission tomography enhancersProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRatio Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesRatio Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A